Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Tango Therapeutics Inc (NASDAQ: TNGX) was $6.82 for the day, up 1.04% from the previous closing price of $6.75. In other words, the price has increased by $1.04 from its previous closing price. On the day, 1.29 million shares were traded. TNGX stock price reached its highest trading level at $7.105 during the session, while it also had its lowest trading level at $6.68.
Ratios:
Our analysis of TNGX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.26 and its Current Ratio is at 6.26. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 17, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On February 12, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $18.Piper Sandler initiated its Overweight rating on February 12, 2024, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 04 ’25 when Barry Douglas sold 2,774 shares for $2.99 per share. The transaction valued at 8,289 led to the insider holds 68,570 shares of the business.
Barry Douglas sold 2,556 shares of TNGX for $8,081 on Feb 05 ’25. The General Counsel now owns 66,014 shares after completing the transaction at $3.16 per share. On Feb 04 ’25, another insider, Beckman Daniella, who serves as the Chief Financial Officer of the company, sold 4,284 shares for $2.99 each. As a result, the insider received 12,801 and left with 154,232 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 739247104 and an Enterprise Value of 559470400. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.03 while its Price-to-Book (P/B) ratio in mrq is 4.42. Its current Enterprise Value per Revenue stands at 13.649 whereas that against EBITDA is -3.902.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.66, which has changed by -0.30122954 over the last 52 weeks, in comparison to a change of 0.16932249 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $12.02, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 51.65%, while the 200-Day Moving Average is calculated to be 100.16%.
Shares Statistics:
TNGX traded an average of 2.95M shares per day over the past three months and 1531050 shares per day over the past ten days. A total of 108.11M shares are outstanding, with a floating share count of 58.92M. Insiders hold about 45.64% of the company’s shares, while institutions hold 58.07% stake in the company. Shares short for TNGX as of 1752537600 were 21525555 with a Short Ratio of 7.29, compared to 1749772800 on 15669874. Therefore, it implies a Short% of Shares Outstanding of 21525555 and a Short% of Float of 23.95.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Tango Therapeutics Inc (TNGX) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.28 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.14 and -$1.54 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.29, with 8.0 analysts recommending between -$1.03 and -$1.58.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $8.5M to a low estimate of $4.54M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $19.88MFor the next quarter, 7 analysts are estimating revenue of $6.77M. There is a high estimate of $8.5M for the next quarter, whereas the lowest estimate is $4.77M.
A total of 7 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $42.07M, while the lowest revenue estimate was $21.57M, resulting in an average revenue estimate of $28.92M. In the same quarter a year ago, actual revenue was $42.07MBased on 7 analysts’ estimates, the company’s revenue will be $29.45M in the next fiscal year. The high estimate is $42.07M and the low estimate is $21.57M.
